Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 291 to 300 of 432 total matches.
Mepolizumab (Nucala) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016 (Issue 1486)
Chung et al. International ERS/ATS guidelines on definition, evaluation
and treatment of severe asthma ...
The FDA has approved mepolizumab (Nucala - GSK), a
subcutaneously injected humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for maintenance
treatment of severe asthma in patients ≥12 years old
who have an eosinophilic phenotype.
Vonoprazan (Voquezna) for Nonerosive GERD
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
(Voquezna – Phathom), which was approved earlier
for treatment of erosive esophagitis, has now ...
The potassium-competitive acid blocker vonoprazan
(Voquezna – Phathom), which was approved earlier
for treatment of erosive esophagitis, has now been
approved by the FDA for relief of heartburn associated
with nonerosive gastroesophageal reflux disease
(GERD) in adults. Vonoprazan is also available
copackaged with amoxicillin (Voquezna Dual Pak) and
with amoxicillin and clarithromycin (Voquezna Triple
Pak) for treatment of Helicobacter pylori infection.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):164-6 doi:10.58347/tml.2024.1713c | Show Introduction Hide Introduction
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014 (Issue 1454)
drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants ...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.
Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis
The Medical Letter on Drugs and Therapeutics • Aug 19, 2013 (Issue 1423)
in addition to other drugs for treatment of adults
with multidrug-resistant pulmonary tuberculosis
(MDR-TB ...
Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a
diarylquinoline antimycobacterial, has been given
accelerated approval by the FDA as an orphan drug
for use in addition to other drugs for treatment of adults
with multidrug-resistant pulmonary tuberculosis
(MDR-TB). It is the first drug approved specifically to
treat MDR-TB.
Pentamidine Aerosol To Prevent Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989 (Issue 802)
as 60%. Therefore, the new US Public Health Service
guidelines recommend PCP prophylaxis for HIV ...
Pneumocystis carinii pneumonia (PCP) occurs in nearly 80% of patients with the acquired immune deficiency syndrome (AIDS) and is a common cause of morbidity and mortality. Oral trimethoprim-sulfamethoxazole (Bactrim; and others), intravenous isethionate (Pentam 300) and other systemic drugs have been used to prevent PCP, but in AIDS patients, all of these agents can occasionally cause severe adverse effects (Medical Letter, 30:94, 1988). Recently, the US Food and Drug Administration approved marketing of aerosolized pentamidine isethionate (NebuPent - LyphoMed) for this indication. Another...
A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)
The Medical Letter on Drugs and Therapeutics • Oct 31, 2011 (Issue 1376)
for ibuprofen and naproxen are for treatment of osteoarthritis or rheumatoid arthritis; the doses of famotidine ...
The FDA has approved Duexis (Horizon), a fixed-dose
combination of the nonsteroidal anti-inflammatory drug
(NSAID) ibuprofen and the H2-receptor antagonist
(H2RA) famotidine, for symptomatic relief of osteoarthritis
and rheumatoid arthritis and to decrease the risk of
developing gastric and duodenal ulcers in patients at
risk for NSAID-associated ulcers. Vimovo, a combination
of the NSAID naproxen and the proton pump
inhibitor (PPI) esomeprazole, is also approved by the
FDA for prevention of NSAID-associated gastric ulcers.
An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
injected, single-dose, prefilled
epinephrine syringe (Symjepi –
Adamis/Sandoz) for emergency
treatment ...
The FDA has approved a manually
injected, single-dose, prefilled
epinephrine syringe (Symjepi –
Adamis/Sandoz) for emergency
treatment of anaphylaxis. The new
device is approved in 0.3- and
0.15-mg strengths for treatment of
patients weighing ≥30 kg and 15 to
30 kg, respectively; only the 0.3-mg
strength is currently available.
According to Sandoz, Symjepi will be made available
first to institutions and later to the retail market.
Caplacizumab (Cablivi) for iTTP
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
exchange and immunosuppressive therapy
for treatment of immune-mediated thrombotic
thrombocytopenic ...
Caplacizumab-yhdp (Cablivi – Sanofi /Genzyme), a
von Willebrand factor-directed antibody fragment, has
been approved by the FDA for use in combination with
plasma exchange and immunosuppressive therapy
for treatment of immune-mediated thrombotic
thrombocytopenic purpura (iTTP; formerly called
acquired thrombotic thrombocytopenic purpura
[aTTP]) in adults. It is the first drug to be approved in
the US for this indication.
TNF Inhibitors for Crohn's Disease: When, Which, and for How Long
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013 (Issue 1432)
) – are approved by the FDA
for treatment of moderately to severely active Crohn’s
disease in adults who have had ...
Three tumor necrosis factor (TNF) inhibitors – infliximab
(Remicade), adalimumab (Humira), and certolizumab
pegol (Cimzia) – are approved by the FDA
for treatment of moderately to severely active Crohn’s
disease in adults who have had an inadequate
response to conventional therapy. Infliximab is also
FDA-approved for the same indication in children ≥6
years old and for treatment of fistulas in adults. All 3
TNF inhibitors have been shown to reduce the signs
and symptoms of Crohn's disease in clinical trials.
They have been associated with adverse effects such
as...
Golimumab (Simponi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2014 (Issue 1439)
continuous treatment with corticosteroids.
Golimumab was approved earlier for treatment
of rheumatoid ...
The FDA has approved golimumab (Simponi – Janssen),
a fully human monoclonal antibody specific for tumor necrosis
factor (TNF) alpha, for induction and maintenance
of remission in patients with moderate to severe ulcerative
colitis who do not respond to or cannot tolerate other
therapies or who require continuous treatment with corticosteroids.
Golimumab was approved earlier for treatment
of rheumatoid arthritis, psoriatic arthritis, and ankylosing
spondylitis. It is the third TNF inhibitor to be approved for
use in ulcerative colitis.